Screener
Janux Therapeutics JANX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating lease right-of-use assets and liabilities, net | (74) | (11) |
| Net cash provided by (used in) operating activities | 147 | (40,837) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (475) | (844) |
| Purchases of short-term investments | (257,593) | (463,976) |
| Maturities of short-term investments | 227,570 | 125,990 |
| Net cash used in investing activities | (30,498) | (338,830) |
| Cash flows from financing activities |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's capex?
- Janux Therapeutics (JANX) reported capex of $202K in Q2 2026.
- How has Janux Therapeutics's capex changed year-over-year?
- Janux Therapeutics's capex decreased by 57.3% year-over-year, from $473K to $202K.
- What is the long-term trend for Janux Therapeutics's capex?
- Over 4 years (2021 to 2025), Janux Therapeutics's capex has grown at a -8.4% compound annual growth rate (CAGR), from $1.48M to $1.04M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Janux Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude